2012 | Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
| BMC GENOMICS |
2012 | Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer | INTERNATIONAL JOURNAL OF ONCOLOGY |
2011 | Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells | BREAST CANCER RESEARCH AND TREATMENT |
2010 | Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
2007 | Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer | GENOMICS |
2010 | Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray | JOURNAL OF SURGICAL ONCOLOGY |
2009 | Identification of significant regional genetic variations using continuous CNV values in aCGH data | GENOMICS |
2019 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
| Cancer Research and Treatment |
2008 | Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions
| BMC BIOINFORMATICS |
2009 | In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer | GENOMICS |
2015 | Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
| CANCER RESEARCH AND TREATMENT |
2013 | Increased Alternative Lengthening of Telomere Phenotypes of Telomerase-negative Immortal Cells upon Trichostatin – A Treatment | ANTICANCER RESEARCH |
2009 | Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer | JOURNAL OF SURGICAL ONCOLOGY |
2011 | Inflammatory and tumor stimulating responses after laparoscopic sigmoidectomy
| YONSEI MEDICAL JOURNAL |
2014 | Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer | JOURNAL OF PSYCHOSOMATIC RESEARCH |
2003 | Infusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
2019 | Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer | GASTRIC CANCER |
2008 | Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene
| CANCER RESEARCH |
2021 | Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer | CELLULAR ONCOLOGY |
2007 | Integrated in silico and biological validation of the blocking effect of C(o)t-1 DNA on microarray-CGH | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
2006 | Intermediate Dose 5-Fluorouracil-Induced Encephalopathy
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
2001 | Intravenous 5-Fluorouracil Versus Oral Doxifluridine as Preoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Prospective Randomized Trials
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
2007 | Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2010 | Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine? | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
2007 | Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment | JOURNAL OF CLINICAL ONCOLOGY |
2004 | Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell Lymphomas | LEUKEMIA & LYMPHOMA |
2015 | LAMC2 enhances the metastatic potential of lung adenocarcinoma | CELL DEATH AND DIFFERENTIATION |
2019 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
| Cancer Research and Treatment |
2016 | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial | JOURNAL OF CLINICAL ONCOLOGY |
2014 | Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study | JOURNAL OF CLINICAL ONCOLOGY |
2001 | Leptomeningeal Carcinomatosis in Solid Tumors ; Clinical Manifestation and Treatment
| Journal of the Korean Cancer Association (대한암학회지) |
2006 | Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
| CANCER RESEARCH AND TREATMENT |
2021 | MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
| FUTURE ONCOLOGY |
2019 | Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
| FUTURE ONCOLOGY |
2022 | Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A | ESMO OPEN |
2018 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial | ANNALS OF SURGICAL ONCOLOGY |
2013 | Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
| JOURNAL OF RADIATION RESEARCH |
1998 | Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
2018 | MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. | JOURNAL OF SURGICAL ONCOLOGY |
2012 | Methylation status of lamin A/C in gastric cancer cell lines | HEPATO-GASTROENTEROLOGY |
2011 | MMP-2 as a putative biomarker for carcinomatosis in gastric cancer | HEPATO-GASTROENTEROLOGY |
2004 | MN/CA9 촉진자를 가진 replication-competent 아데노바이러스를 이용한 신세포암에 대한 종양 특이적 유전자요법
| KOREAN JOURNAL OF UROLOGY |
2008 | Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer | CANCER LETTERS |
1999 | Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer | International Journal of Molecular Medicine |
2017 | Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines | BIOCHEMICAL PHARMACOLOGY |
2007 | Molecular basis of the differences between normal and tumor tissues of gastric cancer | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE |
2021 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses | HEPATOLOGY |
2021 | Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
| ANNALS OF ONCOLOGY |
2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
2001 | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer | CANCER LETTERS |
2022 | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
2007 | Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
| ONCOLOGIST |
2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
2008 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
2005 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
| ANNALS OF ONCOLOGY |
2016 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
| ONCOTARGET |
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |